Drug Search Results

Rabacfosadine

Alternative Names: rabacfosadine, gs-9219, gs9219, gs 9219
Latest Update: 2024-06-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: DNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Rabacfosadine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
GS-US-193-0101	P2	Terminated	Lymphoma, B-Cell\|Leukemia, Plasma Cell\|Lymphoma, Non-Hodgkin\|Chronic Lymphoid Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Multiple Myeloma	2010-07-01

Recent News Events

Date	Type	Title
05/01/2024	PubMed	Novel Treatments for Lymphoma.
06/01/2024	PubMed	Alternating rabacfosadine and doxorubicin for treatment of naive canine lymphoma.
03/21/2023	News Article	Animal Healthcare Market Size Worth USD 84.98 Billion, Globally, by 2030 at 9.81% CAGR - Exclusive Report by Facts & Factors
06/01/2022	PubMed	Tanovea-CA1® (Rabacfosadine) beim caninen Lymphom.
07/15/2021	News Article	FDA Grants First Full Approval for Treatment of Lymphoma in Dogs

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions